Healthcare
China Medical System Holdings Ltd(CHSYF)
Live Price
Offline$1.35
+0.00% today
1Y Change
+45.05%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $26.84B
- Revenue Growth
- +7.1%
- EPS Growth
- -10.4%
- Dividend Yield
- 2.6%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
China Medical System Holdings Ltd (CHSYF) is a Healthcare stock with a market cap of $26.84B and listed on OTC. The stock last traded around $1.35 and up 45.1% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +7.1%, EPS growth of -10.4%, a dividend yield of 2.6%. What stands out right now is revenue +7.1%, EPS -10.4%, free cash flow -70.0% with operating margin 19.2% and ROIC 5.8%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 18.0 and price/sales 3.3. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines CHSYF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.1% vs +7.6% peer median
Operating Margin
Near sector median
+19.2% vs +19.4% peer median
P/E
Below sector median
18.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 16, 2026 with an EPS surprise of -20.7% and a revenue surprise of -0.5%.
The operating picture looks softer than before
Revenue is at +7.1% and EPS is at -10.4%, with operating margin around 19.2%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 16, 2026 | -20.7% | +0.0% | +0.0% | +0.0% |
2025 Aug 18, 2025 | +5.1% | +0.0% | +0.0% | +0.0% |
2025 Mar 17, 2025 | -14.1% | +0.0% | +0.0% | +63.0% |
Benchmark Edge
CHSYF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CHSYF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CHSYF Max Drawdown
-17.47%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CHSYF and SPY.
Company Overview
China Medical System Holdings Ltd
OTC
China Medical System Holdings Limited is a specialty pharmaceutical company that engages in the development and distribution of branded prescription medicines in China. The company's primary function is to enhance the availability of high-quality and innovative medicines across a spectrum of therapeutic areas. It focuses on improving patient outcomes by offering a comprehensive portfolio of pharmaceuticals, primarily in the fields of cardiovascular, pediatric, and orthopedics care. China Medical System Holdings collaborates extensively with both domestic and international firms to license and market their products in China, thereby leveraging a robust distribution network. Its significant role in the Chinese healthcare market is underscored by its commitment to addressing unmet medical needs and promoting better health outcomes. The company's efforts in expanding its product offerings and its strategic investments in research and development have positioned it as a critical player in the pharmaceutical sector, catering to a vast and growing patient population. Established in 1995, China Medical System Holdings maintains a strong presence in the Chinese healthcare industry, fostering a dynamic interface between global pharmaceutical advancements and Chinese health priorities.
- Leadership
- Dr. Kong Lam
- Employees
- 6.4k
- Street Address
- Island Place Tower, Unit 2106 21st Floor 510 Kings Road
- Mailing
- North Point
- Region
- North Point, Hong Kong
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.0
- EV/EBITDA
- 13.7
- Price/Sales
- 3.3
- Price/Book
- 1.5
Growth
- Revenue
- +7.1%
- EPS
- -10.4%
- Free Cash Flow
- -70.0%
Profitability
- Gross Margin
- 71.5%
- Operating Margin
- 19.2%
- Net Margin
- 18.2%
- ROE
- 8.6%
- ROIC
- 5.8%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 6.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.